Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation
2018559 citationsJanine Doorduin, Rudi Dierckx et al.profile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
This map shows the geographic impact of Rudi Dierckx's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rudi Dierckx with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rudi Dierckx more than expected).
This network shows the impact of papers produced by Rudi Dierckx. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rudi Dierckx. The network helps show where Rudi Dierckx may publish in the future.
Co-authorship network of co-authors of Rudi Dierckx
This figure shows the co-authorship network connecting the top 25 collaborators of Rudi Dierckx.
A scholar is included among the top collaborators of Rudi Dierckx based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Rudi Dierckx. Rudi Dierckx is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Oosting, Sjoukje F., Thijs H. Oude Munnink, Marjolijn N. Lub–de Hooge, et al.. (2012). Serial Zr-89-bevacizumab PET Imaging in Metastatic Renal Cell Carcinoma Patients treated with Sunitinib, or Bevacizumab Plus Interferon.. Data Archiving and Networked Services (DANS).
11.
Ramakrishnan, Nisha K., Anna A. Rybczynska, Csaba Nyakas, et al.. (2011). MicroPET scans of rodents with spontaneous pituitary tumors, using the sigma ligand C-11-SA4503. Data Archiving and Networked Services (DANS).1 indexed citations
12.
Hooge, Marjolijn N. Lub–de, Adrienne H. Brouwers, Johan R. de Jong, et al.. (2010). VEGF-SPECT with In-111-bevacizumab in stage III/IV melanoma patients. European Journal of Nuclear Medicine and Molecular Imaging. 37.1 indexed citations
Glaudemans, Andor W.J.M., et al.. (2009). Bone metastases, a translational and clinical approach. Springer US.16 indexed citations
15.
Malviya, Gaurav, Bruno Laganà, Francesca Milanetti, et al.. (2008). Use of 99m-technetium labelled Rituximab for imaging of patients with chronic inflammatory diseases. Data Archiving and Networked Services (DANS).4 indexed citations
Peremans, Kathelijne, Kurt Audenaert, Frank Coopman, et al.. (2002). Functional brain imaging of serotonin-2A receptors in impulsive dogs: a pilot study. Vlaams Diergeneeskundig Tijdschrift. 71(5). 340–347.3 indexed citations
19.
Staelens, Ludovicus, Filip Dumont, Ruth Oltenfreiter, et al.. (2001). Title: Synthesis, biodistribution and blocking studies in mice of a new 123I-labeled dopamine D3 antagonist Dierckx RA, Slegers G. Ghent University Academic Bibliography (Ghent University).1 indexed citations
20.
Osmanagaoglu, Kaan, et al.. (1995). The course of the thymic rebound phenomenon in Burkitt lymphoma patients: a retrospective study. European Journal of Nuclear Medicine and Molecular Imaging. 22(8). 856–856.2 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.